Since 2003, RegenLab® has been committed to the development of a unique expertise in the design and manufacturing of high-quality medical devices, intended for the preparation of cellular therapies and autologous platelet-rich plasma (PRP) from the patient’s own blood. Bringing these technologies to the United States in 2013, RegenLab® USA offers Regen® A-PRP® and Autologous Thrombin Serum with a focus on product quality, patient safety, and preparation efficiency. Now in 2022, RegenLab is proud to be manufactured in the USA. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.
History: Founded in Switzerland in 2003, Our patient-centered technology has led to over one million treatments provided worldwide using RegenLab® products. In 2017, a new Good Manufacturing Practice (GMP) facility was completed in Mont-sur-Lausanne, Switzerland allowing RegenLab® to increase access to autologous cellular therapies around the world.
